Hemostasis and thrombosis (19)
All Items
-
Natural history of anti-PF4 antibodies in patients with vaccine-induced immune thrombocytopenia and thrombosis
-
Evaluation of an automated platelet aggregation method for detection of congenital or acquired platelet function defects
-
T-TAS® 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion
-
Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology
-
Global hemostasis assays in acute myeloid leukemia: results of an observational prospective study
-
Hormones and thrombosis: the dark side of the moon
-
Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura
-
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding
-
Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects
-
Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers
-
Viscoelastic coagulation testing in Neonatal Intensive Care Units: advantages and pitfalls in clinical practice
-
A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study
-
Thrombosis and bleeding after COVID-19 vaccination: do differences in sex matter?
-
Validation of PLASMIC score in a cohort of patients with suspected thrombotic microangiopathy in an academic medical centre
-
The effect of exosomes released from apheresis platelet concentrates under the impact of gamma irradiation and storage time upon platelet aggregation and hemostasis
-
Heparin-induced thrombocytopenia: effect of heat inactivation of patient’s serum on functional flow cytometric assay results
-
Transfusion of fibrinogen concentrate before dental extractions in patients with afibrinogenemia: a narrative review supported by a case report with a proposed treatment protocol
-
Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin®) in paediatric patients under 6 years of age with severe von Willebrand disease
-
Acquired von Willebrand syndrome in patients with monoclonal gammopathy of undetermined significance investigated using a mechanistic approach
19 Items